What Has Been the Growth Trajectory for the Branded Generics Market in Recent Years?
The branded generics market has seen considerable growth due to a variety of factors.
• The size of the branded generics market has seen robust growth in the past few years. Predicted to expand from $363.49 billion in 2024 to $397.19 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 9.3%.
Factors such as cost-effectiveness, expiration of patents, augmented market reach and access, policy initiatives by the government, as well as healthcare reforms, have contributed to growth in the said historical period.
What Are the Future Growth Projections for the Branded Generics Market?
The branded generics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of branded generics is predicted to expand rapidly in the upcoming years. The market is forecasted to reach a size of $601.4 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.9%.
The anticipated growth during the forecast period can be due to factors like an increased demand for generic biologics, a rise in chronic diseases, the expansion of emerging markets, and a focus on biosimilars. Key trends during the forecast period will be strategic alliances and collaborations, advancements in technology, a concentration on chronic diseases, market amalgamation, and a patient-oriented approach.
What Are The Primary Growth Drivers In The Branded Generics Market?
The uptick in chronic diseases is set to accelerate the growth of the branded generics market. These are persistent illnesses that often remain uncured, but they can be managed and treated effectively. Their rise is largely due to increased tobacco use, poor dietary habits, sedentary lifestyles, high alcohol consumption, among other factors. Globally, consumers are showing preference for branded generics for treating chronic diseases, given they are cheaper than traditional medicine. For example, as per the World Health Organization's (WHO) 2022 Highlights released in September 2022, the Switzerland-based international health organization reported 41 million deaths which constitute 74% of all deaths, were due to noncommunicable diseases (NCDs) or chronic illnesses, annually, across the globe. Therefore, the expanding prevalence of chronic diseases will likely enhance the demand for branded generics in the forecast period.
What Are The Major Segments Within The Branded Generics Market?
The branded generics market covered in this report is segmented –
1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals
Pre-Book The Branded Generics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Branded Generics
Collaborative strategies are a major trend in the branded generics market. Companies engaged in this sector forge partnerships with pertinent entities in order to utilise each other's strengths and enable growth into new territories. For illustration, in September 2024, Biocon Ltd., a pharmaceutical firm from India, initiated a partnership with Tabuk Pharmaceuticals. Biocon's role would be to oversee the development and production of GLP-1 products, making sure they meet high standards for diabetes treatment. Tabuk Pharmaceuticals, on the other hand, will maintain marketing authorization rights and manage the registration, importing, and advocating of these products chiefly across the Middle East, with special emphasis on Saudi Arabia. The deal also provides options for future enlargement into other GLP products, fostering a more diverse range of diabetes therapy. The partnership's goal is to provide distinct health solutions that boost the health of patients in Saudi Arabia and neighboring regions which aligns with the shared goal of both firms to enhance access to healthcare. Tabuk Pharmaceuticals, a company based in Saudi Arabia, markets both branded and generic pharmaceutical goods.
Who Are the Key Players in the Branded Generics Market?
Major companies operating in the branded generics market include:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Sanofi SA
• AstraZeneca plc
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Alkem Laboratories Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Aspen Pharmacare Holdings Limited
• Endo International plc
• Towa Pharmaceutical Co. Ltd.
• Mankind Pharma
• Glenmark Pharmaceuticals
• Par Pharmaceuticals Inc.
• Unichem Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Wockhardt
• Intas Pharmaceuticals Ltd.
• Novartis International AG
• Novo Nordisk A/S
• Zydus Lifesciences Ltd.
What Is The Most Dominant Region In The Branded Generics Market?
North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
